@ARTICLE{Pieczarkowski_Stanisław_Serum_2020, author={Pieczarkowski, Stanisław and Kowalska-Duplaga, Kinga and Kwinta, Przemko and Wędrychowicz, Andrzej and Tomasik, Przemysław and Stochel-Gaudyn, Anna and Fyderek, Krzysztof}, volume={Vol. 60}, number={No 1}, journal={Folia Medica Cracoviensia}, pages={61-74}, howpublished={online}, year={2020}, publisher={Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum}, abstract={B a c k g r o u n d a n d s t u d y a i m s: The aim of the study was to assess the usefulness of serum concentrations of YKL-40/ CHI3L1 (a 40-kilodalton glycoprotein also referred to as chitinase 3 like- 1 — CHI3L1) and PIIINP (N-terminal propeptide of type III procollagen), markers of fibrosis, in the monitoring of inflammatory processes and fibrosis in children with inflammatory bowel disease (IBD). P a t i e n t s a n d m e t h o d s: In 60 patients (41 with Crohn’s disease (CD), 19 with ulcerative colitis (UC)) concentrations of investigated parameters were measured at baseline (day 0), after 3 and after 6–8 weeks of pharmacological treatment. R e s u l t s: PIIINP concentrations were significantly higher in CD patients compared to UC (baseline results: median concentrations 1013.73 vs 78.30 ng/mL; P = 0.06 for the Kruskall-Wallis test; results at 6–8 weeks: 1076.48 vs 53.10 ng/mL, P = 0.01). Fibrosis was clearly present in patients with CD and its severity increased (reflected by both YKL-40/ CHI3L1 and PIIINP concentrations) in 6–8 weeks of follow up, regardless of the treatment used during that time. In patients with UC the levels of YKL-40/CHI3L1 and PIIINP were lower at baseline and further decreased after 6–8 weeks (median concentrations were respectively: 39.5 ng/mL vs 24.7 ng/mL and 78.3 ng/mL vs 53.1 ng/mL). C o n c l u s i o n: Fibrosis was more severe in CD than in UC patients. The marker that more accurately reflected these differences was PIIINP.}, type={Article}, title={Serum concentrations of fibrosis markers in children with inflammatory bowel disease}, URL={http://www.czasopisma.pan.pl/Content/116634/PDF/2020-01-FOMC-07-Pieczarkowski-etal.pdf}, doi={10.24425/fmc.2020.133487}, keywords={YKL-40/CHI3L1, PIIINP, Crohn’s disease, ulcerative colitis}, }